Sapience Therapeutics
Scarsdale, US · Founded 2015 · Delaware corporation · 23 employees on LinkedIn · 5 known investors
Sapience Therapeutics is a clinical-stage biotechnology company developing peptide-based cancer therapies that target traditionally undruggable oncogenic proteins and protein-protein interactions. Its pipeline includes SPEAR peptides that act inside cancer cells and SPARC peptides that act on the outside, with lead candidates lucicebtide (ST101) and ST316 in Phase 2 oncology trials.
Founders & leadership
Sapience Therapeutics was founded in 2015 by Barry Kappel, Ph.D..
BK
Barry Kappel, Ph.D.Founder
AV
Abi Vainstein-HarasinChief Medical Officer
MF
Marisa FrackmaninChief Financial Officer
SI
Seth I. RubininGeneral Counsel
Board
IB
Isaac BlechBoard director
RR
Robert Ruffolo, Ph.D.Board director
DS
David Scheinberg, Ph.D.Board director
Investors · 5
Also in the syndicate · 3
Bristol Myers SquibbKingdon CapitalNexPointlead
Funding
SEC filings, press & company announcements$49.3M disclosed across 3 of 5 rounds · 2015–2022
- $41MSeries BJun 2022 · 2 sources
NexPoint (lead), Bristol Myers Squibb, Eshelman Ventures, Kingdon Capital
Source ↗ - Undisclosed amountSeries BMay 2022
NexPoint (lead), Bristol Myers Squibb, Eshelman Ventures, Kingdon Capital
Source ↗
▶$8MraisedJul 2020 · 83 investors · BiotechnologyRule 506(b)
▶$8MraisedJul 2020 · 83 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christian SchadeDirector
- Barry KappelExecutive Officer, Director
- David ScheinbergDirector
- Howard PienDirector
- Robert RuffoloDirector
- Offering amount
- $30M
- Amount sold
- $8M
- Minimum investment
- $50K
- Sales commissions
- $701.1K
- Placement agents
- Maxim Group LLC
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$22.5MofferedApr 2016 · BiotechnologyRule 506(b)
▶$22.5MofferedApr 2016 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert Ruffolo, Ph.D.Director
- Barry Kappel, Ph.D.Executive Officer, Director
- David Scheinberg, Ph.D.Director
- Howard PienDirector
- Isaac BlechDirector
- Offering amount
- $22.5M
- Minimum investment
- $50K
- Sales commissions
- $800K
- Placement agents
- Maxim Group LLC
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$300KraisedJan 2016 · 3 investors · BiotechnologyRule 506(b)
▶$300KraisedJan 2016 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert Ruffolo, Ph.D.Director
- David Scheinberg, Ph.D.Director
- Isaac BlechDirector
- Barry Kappel, Ph.D.Executive Officer, Director
- Offering amount
- $1M
- Amount sold
- $300K
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Solu23 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Bioworld22 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Sapience Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Sapience Therapeutics do?
- Sapience Therapeutics is a clinical-stage biotechnology company developing peptide-based cancer therapies that target traditionally undruggable oncogenic proteins and protein-protein interactions. Its pipeline includes SPEAR peptides that act inside cancer cells and SPARC peptides that act on the outside, with lead candidates lucicebtide (ST101) and ST316 in Phase 2 oncology trials.
- Who founded Sapience Therapeutics?
- Sapience Therapeutics was founded by Barry Kappel, Ph.D. in 2015.
- Who are Sapience Therapeutics's investors?
- Sapience Therapeutics's investors include Connectivity Ventures, Eshelman Ventures, LLC.
- How much funding has Sapience Therapeutics raised?
- Sapience Therapeutics has disclosed $49.3M raised across 3 of its 5 known rounds.
- Where is Sapience Therapeutics headquartered?
- Sapience Therapeutics is headquartered in Scarsdale, US.